BOSTON and ATLANTA, May 4, 2023
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT)
("Inhibikase" or "Company"), a clinical-stage pharmaceutical
company developing protein kinase inhibitor therapeutics to modify
the course of Parkinson's disease, Parkinson's-related disorders
and other diseases of the Abelson Tyrosine Kinases, today
announced that Dr. Milton Werner,
Ph.D., President & Chief Executive Officer of Inhibikase, will
deliver a presentation at the Sidoti Micro-Cap Virtual Conference
being held on May 10-11, 2023.
Presentation Details:
Event: Sidoti Micro-Cap Virtual Conference
Presentation Date: Thursday, May 11, 2023
Presentation Time: 1:45pm ET
Location: Virtual; Track 1
A live webcast of the presentation will be accessible on the
Company's website in the Investors section under News & Events
at www.inhibikase.com. A replay of the webcast will be available on
the Inhibikase website for approximately 90 days following the
presentation.
About Inhibikase (www.inhibikase.com)
Inhibikase
Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical
company developing therapeutics for Parkinson's disease and related
disorders. Inhibikase's multi-therapeutic pipeline has a primary
focus on neurodegeneration and its lead program IkT-148009, an
Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of
Parkinson's disease inside and outside the brain as well as other
diseases that arise from Ableson Tyrosine Kinases. Its
multi-therapeutic pipeline is pursuing Parkinson's-related
disorders of the brain and GI tract, orphan indications related to
Parkinson's disease such as Multiple System Atrophy, and drug
delivery technologies for kinase inhibitors such as IkT-001Pro, a
prodrug of the anticancer agent imatinib mesylate that the Company
believes will provide a better patient experience with fewer
on-dosing side-effects. The Company's RAMP™ medicinal chemistry
program has identified a number of follow-on compounds to
IkT-148009 to be potentially applied to other cognitive and motor
function diseases of the brain. Inhibikase is headquartered in
Atlanta, Georgia with an office in
Lexington, Massachusetts.
Social Media Disclaimer
Investors and others should
note that we announce material financial information to our
investors using our investor relations website, press releases, SEC
filings and public conference calls and webcasts. The Company
intends to also
use Twitter, Facebook, LinkedIn and YouTube as
a means of disclosing information about the Company, its services
and other matters and for complying with its disclosure obligations
under Regulation FD.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
terminology such as "believes," "expects," "may," "will," "should,"
"anticipates," "plans," or similar expressions or the negative of
these terms and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based on Inhibikase's current expectations and assumptions. Such
statements are subject to certain risks and uncertainties, which
could cause Inhibikase's actual results to differ materially from
those anticipated by the forward-looking statements, including that
results in animal studies may not be replicated in humans.
Important factors that could cause actual results to differ
materially from those in the forward-looking statements include
factors that are delineated in our periodic reports on Form 10-K
and Form 10-Q that we file with the U.S. Securities and Exchange
Commission. Any forward-looking statement in this release speaks
only as of the date of this release. Inhibikase undertakes no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by any
applicable securities laws.
Contacts:
Company Contact:
Milton H.
Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex
Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-sidoti-micro-cap-virtual-conference-301815174.html
SOURCE Inhibikase Therapeutics, Inc.